Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities

Background and Aim:  Helicobacter pylori (H. pylori) eradication rates using the PPI/AC regimen (proton pump inhibitor + amoxicillin + clarithromycin) are declining. We trialed tailoring eradication regimens according to clarithromycin (CAM) susceptibility.

[1]  T Rokkas,et al.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report , 2006, Gut.

[2]  T. Itoi,et al.  Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan. , 2007, Hepato-gastroenterology.

[3]  M. Sasatsu,et al.  Comparison of efficacies of dual therapy and triple therapy using rabeprazole in second‐line eradication of Helicobacter pylori in Japan , 2006 .

[4]  T. Itoi,et al.  The Effectiveness of Packaged Medicine in Eradication Therapy of Helicobacter pylori in Japan , 2006 .

[5]  M. Sasatsu,et al.  Susceptibilities to clarithromycin, amoxycillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995-2001. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  M. Sasatsu,et al.  Development of a Highly Sensitive Method for Detection of Clarithromycin-Resistant Helicobacter pylori from Human Feces , 2005, Current Microbiology.

[7]  P. Hufnagl,et al.  Novel Real-Time PCR Assay for Detection of Helicobacter pylori Infection and Simultaneous Clarithromycin Susceptibility Testing of Stool and Biopsy Specimens , 2004, Journal of Clinical Microbiology.

[8]  N. Sato,et al.  Clarithromycin Resistance, but Not CYP2C-19 Polymorphism, Has a Major Impact on Treatment Success in 7-Day Treatment Regimen for Cure of H. pylori Infection: A Multiple Logistic Regression Analysis , 2001, Digestive Diseases and Sciences.

[9]  H. Isomoto,et al.  High‐dose rabeprazole–amoxicillin versus rabeprazole–amoxicillin–metronidazole as second‐line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection , 2003, Alimentary pharmacology & therapeutics.

[10]  D. Aust,et al.  Detection of Helicobacter pylori in Paraffin-Embedded and in Shock-Frozen Gastric Biopsy Samples by Fluorescent In Situ Hybridization , 2003, Journal of Clinical Microbiology.

[11]  K. Murakami,et al.  Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second‐line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance , 2003, Alimentary pharmacology & therapeutics.

[12]  W. C. Wang,et al.  Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole‐based triple therapies , 2002, Alimentary pharmacology & therapeutics.

[13]  T. Fujioka,et al.  A Multicenter, Double‐Blind Study on Triple Therapy with Lansoprazole, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori in Japanese Peptic Ulcer Patients , 2001, Helicobacter.

[14]  M. Asaka,et al.  Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism , 2001, Alimentary pharmacology & therapeutics.

[15]  A. Andriulli,et al.  Predictors of failure of Helicobacter pylori eradication with the standard ‘Maastricht triple therapy’ , 2001, Alimentary pharmacology & therapeutics.

[16]  H. Sugimura,et al.  Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin , 2001 .

[17]  H. Sugimura,et al.  Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. , 2000, Clinical pharmacology and therapeutics.

[18]  星谷 聡.  Relationship between Eradication Therapy and Clarithromycin-resistant Helicobacter pylori in Japan , 2000 .

[19]  K. Haruma,et al.  Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of Helicobacter pylori in smokers , 2000, Alimentary pharmacology & therapeutics.

[20]  Y. Shiratori,et al.  Detection of Clarithromycin-ResistantHelicobacter pylori Strains by a Preferential Homoduplex Formation Assay , 2000, Journal of Clinical Microbiology.

[21]  Shinichi Takahashi,et al.  Screening for oesophageal adenocarcinoma: an evaluation of a surveillance program for columnar metaplasia of the oesophagus. , 2000 .

[22]  K. Haruma,et al.  Effect of Smoking and Histological Gastritis Severity on the Rate of H. pylori Eradication with Omeprazole, Amoxicillin, and Clarithromycin , 1999, Helicobacter.

[23]  C. Vandenbroucke-Grauls,et al.  Mechanism of clarithromycin resistance in clinical isolates of Helicobacter pylori. , 1996, FEMS microbiology letters.

[24]  D. Graham,et al.  Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori , 1996, Antimicrobial agents and chemotherapy.

[25]  G R Wilkinson,et al.  Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. , 1994, Molecular pharmacology.

[26]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.